Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet,

Slides:

Advertisements

Similar presentations

Effects of AIN457, a Fully Human Antibody to Interleukin- 17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis by Wolfgang Hueber, Dhavalkumar D. Patel,

Advertisements

Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail by James Pettitt, Larry Zeitlin, Do H.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity by Alice P. Liou, Melissa Paziuk, Jesus-Mario Luevano, Sriram.

Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza by Nyall R. London, Weiquan Zhu, Fernando A. Bozza, Matthew.

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase by Mayra García, Arik Cooper, Wei Shi, William Bornmann, Ricardo Carrion,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model by Gerhard Leinenga, and Jürgen Götz Sci Transl Med Volume.

The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice by Peter J. Turnbaugh, Vanessa K. Ridaura, Jeremiah.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 1. MAHALO clinical trial flowchart.

Fig. 4. MATE1 transcription in RCC.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 1. In vitro binding and neutralization activities of C12G6.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Evaluation of clinical responses after infusion of CART19 cells

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 1. Specificity of FolamiR uptake in cancer cells in culture.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

BMS blocks functional responses in primary immune cells driven by IFNα

The microchip-based drug delivery device and overview of study design

Two-mAb cocktail protects macaques against the Makona variant of Ebola virus by Xiangguo Qiu, Jonathan Audet, Ming Lv, Shihua He, Gary Wong, Haiyan Wei,

Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L.

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Presentation transcript:

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet, Alexander Bello, Teresa Cabral, Jim E. Strong, Frank Plummer, Cindy R. Corbett, Judie B. Alimonti, and Gary P. Kobinger Sci Transl Med Volume 4(138):138ra81-138ra81 June 13, 2012 Published by AAAS

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs. ( A ) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow). Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS

Fig. 2 Clinical overview. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS

Fig. 3 EBOV-GP–specific antibody response. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS

Fig. 4 Cellular immune response in surviving animals 21 days after challenge. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS

Fig. 5 Identification of IL-2 and IFN-γ–producing cells upon in vitro stimulation by EBOV-GP peptide pools using flow cytometry. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS

Fig. 6 EBOV-GP sequences isolated from nonsurvivors. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Published by AAAS